• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
REPL

REPL

Replimune Group, Inc.

NASDAQHealthcareBiotechnologyUS

USD9.98

+1.11 (+12.51%)

Rating:C

Company Profile

CEO

Sushil Patel

IPO Date

2018-07-20

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$8.80

Prev. Close

$8.87

Day Low

$8.80

Day High

$10.41

52W Low

$1.50

52W High

$13.24

Market Cap

$0.82B

Volume

8.99M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

28.9%

Avg Negative

18.7%

Avg Neutral

52.1%

News Feed

Replimune to Present at the William Blair Biotech Focus Conference 2021

GlobeNewsWire·7/7/2021·↑ positive

Buy The Replimune Dip Caused By Unrealistic Expectations

Seeking Alpha·6/4/2021·↓ negative

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

GlobeNewsWire
·6/3/2021
·↑ positive

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update

GlobeNewsWire·5/20/2021·↑ positive

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Seeking Alpha·4/30/2021·↓ negative

Replimune to Host Virtual Investor Event on June 3, 2021

GlobeNewsWire·4/28/2021·↓ negative

Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting

GlobeNewsWire·4/12/2021·↑ positive

Replimune to Present at the American Association for Cancer Research Annual Meeting 2021

GlobeNewsWire·3/11/2021·↑ positive

Replimune to Present at Three Upcoming Investor Conferences

GlobeNewsWire·3/4/2021·↑ positive

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

GlobeNewsWire·2/4/2021·↑ positive